Medical Breakthrough Research Starts at the Top!

As an informed investor, nothing – and I do mean nothing – should be higher on your priority list than the people who make a company's success possible. A major part of your research should involve getting to know who's in charge of a company at the top levels and why they're highly qualified.

Without great management, a company can't progress and continue to generate robust profits for long. In order to really assess this, you have to vet a company's corporate-level talent very carefully. Do they have the experience, the know-how, and the vision to take a business to the next level and provide outstanding shareholder value?

As they sift through literally hundreds of contenders, my research team keeps coming back to one emerging name in the pharmaceutical R&D space. It's a company known as Champignon Brands (CAD: SHRM, US: SHRMF), and they've recently brought not just one, but four industry leaders onboard their growing team of experts.

That's practically unheard of, so I had to investigate this further. First of all, this company has an undisputed foothold in a market that's really just in its infancy, conducting R&D and developing patents in psychedelic medicine therapies for mood disorders such as depression and anxiety.

The projected global market for mental health/neurological disorders is expected to reach $128.9 billion by 2025, so Champignon's taking a bite out of a sizable fiscal pie. But again, while it's a massively lucrative business, no company can succeed without a strong foundation in top-level talent.

Champignon Brands really sealed the deal in this area when the company brought Dr. Roger McIntyre onboard as its Chief Executive Officer. His list of credentials is extensive and includes the titles of Professor of Psychiatry and Pharmacology at the University of Toronto, as well as Head of the Mood Disorders Psychopharmacology Unit at the University Health Network.


Dr. Roger McIntyre. Courtesy: University of Toronto

Just as important, Dr. McIntyre is a leading expert in both depressive disorders and psychedelic medicine research and development. As such, he had the vision to develop the Canadian Rapid Treatment Centre of Excellence (CRTCE), a first-mover in Canada in providing rapid-onset, psychedelic-based treatments for individuals with mood disorders.

At around the same time as Champignon selected Dr. McIntyre as the new CEO, the company also released the exciting news that it had appointed Dr. Bill Wilkerson to its board of directors. Dr. Wilkerson is an 8-time award-winning pioneer in workplace mental health who previously served as president of one of Canada's largest health benefits companies, Liberty Health.

On top of all of that, Champignon Brands recently handpicked two industry luminaries to its already star-studded Special Advisory Committee. First is molecular biologist Dr. Joseph Gabriele, who is famous in the medical community for leading the development of the transdermal delivery platform known as Delivra.

Then, just a few days later, Champignon announced the appointment of Jay Kheita to the committee. He's a clinical instructor at the Leslie Dan faculty of pharmacy at the University of Toronto, as well as the founder of AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator, IP aggregator, and solutions provider that's controlled by Champignon Brands.

With two new cornerstone advisors and Dr. Wilkerson on the board of directors and Dr. McIntyre as the newly installed CEO, Champignon Brands is the clear standout among researchers and patent developers in highly-necessary medical treatments for today's tragically prevalent mood disorders.


Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF)!

For further updates on Champignon Brands​, subscribe now!

    We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

    Please read our full disclaimer at